These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 30334421)

  • 1. Decreased serum levels of interleukin-35 among multiple sclerosis patients may be related to disease progression.
    Badihian S; Shaygannejad V; Soleimani P; Mirmosayyeb O; Samee Z; Manouchehri N; Esmaeil N
    J Biol Regul Homeost Agents; 2018; 32(5):1249-1253. PubMed ID: 30334421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic relevance of the C-X-C motif chemokine ligand 13 and interleukin-8 in predicting the transition from clinically isolated syndrome to multiple sclerosis.
    Klíčová K; Mareš J; Sobek O; Rous Z; Rous M; Raška M; Hartung HP
    Eur J Neurosci; 2024 Jun; 59(11):2955-2966. PubMed ID: 38453679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased serum level of IL-37 in patients with multiple sclerosis and neuromyelitis optica.
    Farrokhi M; Rezaei A; Amani-Beni A; Etemadifar M; Kouchaki E; Zahedi A
    Acta Neurol Belg; 2015 Dec; 115(4):609-14. PubMed ID: 26008726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Th17 cells in patients with relapsing-remitting multiple sclerosis: interleukin-17A and interleukin-17F serum levels.
    Babaloo Z; Aliparasti MR; Babaiea F; Almasi S; Baradaran B; Farhoudi M
    Immunol Lett; 2015 Apr; 164(2):76-80. PubMed ID: 25625963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine Profile in Patients with Progressive Multiple Sclerosis and Its Association with Disease Progression and Disability.
    Kallaur AP; Oliveira SR; Simão ANC; Alfieri DF; Flauzino T; Lopes J; de Carvalho Jennings Pereira WL; de Meleck Proença C; Borelli SD; Kaimen-Maciel DR; Maes M; Reiche EMV
    Mol Neurobiol; 2017 May; 54(4):2950-2960. PubMed ID: 27023227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased Level of Caspase-1 in the Serum of Relapsing-remitting Multiple Sclerosis (RRMS) Patients.
    Beheshti M; Salehi Z; Abolfazli R; Shirzad H; Izad M
    Iran J Allergy Asthma Immunol; 2020 Oct; 19(5):534-538. PubMed ID: 33463121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-23 plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects.
    Shajarian M; Alsahebfosoul F; Etemadifar M; Sedaghat N; Shahbazi M; Firouzabadi FP; Dezashibi HM
    Immunol Invest; 2015; 44(1):36-44. PubMed ID: 25083738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Untreated relapsing remitting multiple sclerosis patients show antibody production against latent Epstein Barr Virus (EBV) antigens mainly in the periphery and innate immune IL-8 responses preferentially in the CNS.
    Sisay S; Lopez-Lozano L; Mickunas M; Quiroga-Fernández A; Palace J; Warnes G; Alvarez-Lafuente R; Dua P; Meier UC
    J Neuroimmunol; 2017 May; 306():40-45. PubMed ID: 28385186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL17 and IFNgamma production by peripheral blood mononuclear cells from clinically isolated syndrome to secondary progressive multiple sclerosis.
    Frisullo G; Nociti V; Iorio R; Patanella AK; Marti A; Caggiula M; Mirabella M; Tonali PA; Batocchi AP
    Cytokine; 2008 Oct; 44(1):22-5. PubMed ID: 18793860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of IL-17A in patients with relapsing-remitting multiple sclerosis treated with interferon-β.
    Bălaşa R; Bajko Z; Huţanu A
    Mult Scler; 2013 Jun; 19(7):885-90. PubMed ID: 23207971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-1ra serum levels in disease stages of MS--a marker for progression?
    Heesen C; Sieverding F; Buhmann C; Gbadamosi J
    Acta Neurol Scand; 2000 Feb; 101(2):95-7. PubMed ID: 10685855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between interleukin-32 polymorphism and multiple sclerosis.
    Morsaljahan Z; Rafiei A; Valadan R; Abedini M; Pakseresht M; Khajavi R
    J Neurol Sci; 2017 Aug; 379():144-150. PubMed ID: 28716229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations in serum levels of IL-17 in contrast to TNF-alpha correspond to disease-modifying treatment in relapsing-remitting multiple sclerosis.
    Trenova AG; Slavov GS; Manova MG; Draganaova-Filipova MN; Mateva NG; Miteva LD; Stanilova SA
    Scand J Clin Lab Invest; 2017 Jul; 77(4):283-288. PubMed ID: 28319417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micro-RNA 18b and interleukin 17A profiles in relapsing remitting multiple sclerosis.
    Mohamed MS; Nahrery EMAE; Shalaby N; Hussein M; Aal RAE; Mohamed MM
    Mult Scler Relat Disord; 2019 Feb; 28():226-229. PubMed ID: 30623862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated IL-38 Serum Levels in Newly Diagnosed Multiple Sclerosis and Systemic Sclerosis Patients.
    Zarrabi M; Nazarinia M; Rahimi Jaberi A; Gholijani N; Amirghofran Z
    Med Princ Pract; 2021; 30(2):146-153. PubMed ID: 33080590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Levels of Biomarkers of Immune Activation and Associations With Neurological Impairment in Relapsing-Remitting Multiple Sclerosis Patients During Remission.
    Witkowska AM; Socha K; Kochanowicz J; Karpińska E; Jakoniuk M; Zujko ME; Wilkiel M; Borawska MH; Mariak Z
    Biol Res Nurs; 2016 Jan; 18(1):113-9. PubMed ID: 25911236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating levels of interleukin-35 in patients with multiple sclerosis: evaluation of the influences of FOXP3 gene polymorphism and treatment program.
    Jafarzadeh A; Jamali M; Mahdavi R; Ebrahimi HA; Hajghani H; Khosravimashizi A; Nemati M; Najafipour H; Sheikhi A; Mohammadi MM; Daneshvar H
    J Mol Neurosci; 2015 Apr; 55(4):891-7. PubMed ID: 25326790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-27 plasma level in relapsing remitting multiple sclerosis subjects: The double-faced cytokine.
    Naderi S; Hejazi Z; Shajarian M; Alsahebfosoul F; Etemadifar M; Sedaghat N
    J Immunoassay Immunochem; 2016; 37(6):659-70. PubMed ID: 27249307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA 26a Expression in Peripheral Blood Mononuclear Cells and Correlation with Serum Interleukin-17 in Relapsing-Remitting Multiple Sclerosis Patients.
    Mahmoud FM; ElSheshtawy NM; Zaki WK; Zamzam DM; Fahim NM
    Egypt J Immunol; 2017 Jun; 24(2):71-82. PubMed ID: 29528581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-33 plasma levels in patients with relapsing-remitting multiple sclerosis.
    Alsahebfosoul F; Rahimmanesh I; Shajarian M; Etemadifar M; Sedaghat N; Hejazi Z; Naderi S
    Biomol Concepts; 2017 Mar; 8(1):55-60. PubMed ID: 28107165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.